Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease
- 10 November 2023
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (12) , 1797-1810
Abstract
Purpose of Review Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR’s role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target. Recent Findings Clinical, genetic, and experimental evidence supports suPAR’s role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling. Summary Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.Keywords
Funding Information
- National Institutes of Health (NHLBI R01HL153384)
- Gilead Sciences Research Scholar Program
This publication has 89 references indexed in Scilit:
- Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk ScoreInternational Journal of Cardiology, 2013
- Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous InterventionThe American Journal of Cardiology, 2012
- Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer StudyAtherosclerosis, 2012
- Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-studyThrombosis Research, 2011
- Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migrationMolecular Immunology, 2011
- Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general populationJournal of Internal Medicine, 2010
- Regulation of cell signalling by uPARNature Reviews Molecular Cell Biology, 2010
- Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPARFrontiers in Bioscience-Landmark, 2009
- The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patientsThrombosis Research, 2008
- Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient miceJournal of Cellular Physiology, 2004